Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 73, Issue 3, 2016, Pages 294-298

  Gallant, Joel ^a   Brunetta, Jason ^b   Crofoot, Gordon ^c   Benson, Paul ^d   Mills, Anthony ^e   Brinson, Cynthia ^f   Oka, Shinichi ^g   Cheng, Andrew ^h   Garner, Will ^h   Fordyce, Marshall ^h   Das, Moupali ^h   McCallister, Scott ^h  

^a Southwest CARE Center   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Gordon Crofoot Research   (United States)

^d Be Well Medical Center   (United States)

^e Southern California s Men s Medical Group Men s Health Foundation   (United States)

^f Central Texas Clinical Research   (United States)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h GILEAD SCIENCES   (United States)

Author keywords

bone; coinfection; elvitegravir; HBV; HIV; renal; TAF; tenofovir alafenamide

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; BIOCHEMICAL MARKER; CHOLESTEROL; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; CREATININE; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; DRUG COMBINATION; ELVITEGRAVIR; GS-7340; QUINOLONE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCREASED APPETITE; KIDNEY FUNCTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SEROCONVERSION; SIDE EFFECT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; COBICISTAT; COINFECTION; DRUG COMBINATIONS; DRUG SUBSTITUTION; EMTRICITABINE; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUINOLONES; TREATMENT OUTCOME;

EID: 84966709419     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001069     Document Type: Article

References (21)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents; 2015:1-166. Available at: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed January 23, 2016
2. Huldrych F, Gunthard HF, Aberg JA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410-425
3. (EACS) EACS. EACS Guideline Version 8.0; 2015. European AIDS Clinical Society. Available at http://www.eacsociety.org/guidelines/eacsguidelines/ eacs-guidelines.html. Accessed January 23, 2016
4. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780
5. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care and STDS. 2008;22:99-103
6. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, hiv-1-infected adults: 48-week results from the ASSERT Study. J Acquir Immune Defic Syndr. 2010;55:49-57
7. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972
8. Schafer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency virus infection. Pharmacotherapy. 2013;33:665-682
9. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203: 1791-1801
10. Van Rompay KKA, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160
11. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385:2606-2615
12. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet. 2015;16:43-52
13. Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. J Acquir Immune Defic Syndr. 2015;71:530-537
14. Gaur A, Fourie J, Chokephaibulkit K, et al. Pharmacokinetics, efficacy and safety of an integrase inhibitor-based single-tablet regimen in HIVinfected treatment-naive adolescents [Poster 909]. Paper presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA
15. Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62:533-540
16. Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59:3563-3569
17. Gilead Sciences Inc., Foster City, CA. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B. Foster City, CA; 2016
18. METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1 pt 1):15-20
19. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-988
20. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl JMed. 2008;359: 2442-2455
21. Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73-79